Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 41, 2011, Pages 17141-17146

  Hu, Yi ^a   Chopra, Vanita ^b   Chopra, Raman ^b   Locascio, Joseph J ^a,b   Liao, Zhixiang ^a   Ding, Hongliu ^a   Zheng, Bin ^a   Matson, Wayne R ^c   Ferrante, Robert J ^d,e   Rosas, H Diana ^b   Hersch, Steven M ^b   Scherzer, Clemens R ^a,b,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c New England Veterans Administration   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f The Harvard Center for Neurodegeneration & Repair   (United States)

Author keywords

Gene expression; macroH2A; Sodium phenylbutyrate; Transcriptional profiling

Indexed keywords

4 PHENYLBUTYRIC ACID; DOPAMINE; DOPAMINE 2 RECEPTOR; HISTONE H2A; HISTONE H2A FAMILY MEMBER Y; HISTONE H2A1; HUNTINGTIN; MESSENGER RNA; PHOSPHOPROTEIN DARPP 32; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE CONTROL STUDY; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE COURSE; FRONTAL CORTEX; GENETIC ASSOCIATION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); UPREGULATION;

ADULT; AGED; ANIMALS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; FEMALE; FRONTAL LOBE; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HUNTINGTON DISEASE; LONGITUDINAL STUDIES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; MIDDLE AGED; NERVE DEGENERATION; RNA, MESSENGER;

ANIMALIA;

EID: 80054742094     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1104409108     Document Type: Article

References (44)

1. Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19:233-238. (Pubitemid 36511427)
2. van der Burg JMM, Björkqvist M, Brundin P (2009) Beyond the brain: Widespread pathology in Huntington's disease. Lancet Neurol 8:765-774.
3. Panov AV, et al. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5:731-736. (Pubitemid 34827590)
4. Maglione V, et al. (2006) The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea. Neurosci Lett 393:27-30. (Pubitemid 41739648)
5. Stoy N, et al. (2005) Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 93:611-623. (Pubitemid 40617621)
6. Luthi-Carter R, et al. (2002) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: Parallel changes in muscle and brain. Hum Mol Genet 11: 1911-1926.
7. Borovecki F, et al. (2005) Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA 102:11023-11028. (Pubitemid 41105986)
8. Runne H, et al. (2007) Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci USA 104:14424-14429. (Pubitemid 350003277)
9. Shi LM, et al. MAQC Consortium (2006) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24:1151-1161.
10. Scherzer CR, Jensen RV, Gullans SR, Feany MB (2003) Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Hum Mol Genet 12:2457-2466. (Pubitemid 37220410)
11. Scherzer CR, et al. (2004) Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol 61:1200-1205. (Pubitemid 39062672)
12. Zheng B, et al. (2010) PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2:52ra73.
13. Schadt EE, et al. (2005) An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 37:710-717. (Pubitemid 41754887)
14. Scherzer CR (2009) Chipping away at diagnostics for neurodegenerative diseases. Neurobiol Dis 35:148-156.
15. Scherzer CR, et al. (2007) Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci USA 104:955-960. (Pubitemid 46154718)
16. Scherzer CR, et al. (2008) GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci USA 105:10907-10912.
17. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121. (Pubitemid 32397092)
18. Angelov D, et al. (2003) The histone variant macroH2A interferes with transcription factor binding and SWI/SNF nucleosome remodeling. Mol Cell 11:1033-1041. (Pubitemid 36566324)
19. Mermoud JE, Costanzi C, Pehrson JR, Brockdorff N (1999) Histone macroH2A1.2 relocates to the inactive X chromosome after initiation and propagation of X-inactivation. J Cell Biol 147:1399-1408. (Pubitemid 30027396)
20. Doyen CM, et al. (2006) Mechanism of polymerase II transcription repression by the histone variant macroH2A. Mol Cell Biol 26:1156-1164.
21. Burke JR, et al. (1996) Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 2:347-350.
22. Bae B-I, et al. (2006) Mutant huntingtin: Nuclear translocation and cytotoxicity mediated by GAPDH. Proc Natl Acad Sci USA 103:3405-3409. (Pubitemid 43346481)
23. Vonsattel JP, et al. (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577.
24. Selemon LD, Rajkowska G, Goldman-Rakic PS (2004) Evidence for progression in frontal cortical pathology in late-stage Huntington's disease. J Comp Neurol 468: 190-204. (Pubitemid 37490352)
25. Beal MF, Ferrante RJ (2004) Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 5:373-384. (Pubitemid 38568498)
26. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465:11-26. (Pubitemid 37075677)
27. Rising AC, et al. (2011) Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats. Exp Neurol 228:173-182.
28. Kuhn A, et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16: 1845-1861. (Pubitemid 47244533)
29. Lin CH, et al. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 10:137-144. (Pubitemid 32098123)
30. Sadri-Vakili G, Cha JHJ (2006) Mechanisms of disease: Histone modifications in Huntington's disease. Nat Clin Pract Neurol 2:330-338. (Pubitemid 43811543)
31. Sadri-Vakili G, et al. (2007) Histones associated with downregulated genes are hypoacetylated in Huntington's disease models. Hum Mol Genet 16:1293-1306. (Pubitemid 47055125)
32. Ferrante RJ, et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23:9418-9427. (Pubitemid 37323042)
33. Gardian G, et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280:556-563. (Pubitemid 40165021)
34. Steffan JS, et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743. (Pubitemid 33009952)
35. Li XN, et al. (2004) Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 10:1150-1159.
36. Ryu H, et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93:1087-1098. (Pubitemid 40776564)
37. Collins AF, et al. (1995) Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: A clinical trial. Blood 85:43-49.
38. Mercuri E, et al. (2007) Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 68:51-55. (Pubitemid 46058552)
39. Woodcock J (2004) A framework for biomarker and surrogate endpoint use in drug development, US Food and Drug Administration. Available at www.fda.gov/ohrms/ dockets/ac/04/.../2004-4079S2-03-Woodcock.ppt. Accessed on November 4, 2010.
40. Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4:309-314.
41. Hennecke G, Scherzer CR (2008) RNA biomarkers of Parkinson's disease: Developing tools for novel therapies. Biomarkers in Medicine 2:41-53. (Pubitemid 351445079)
42. Whitney AR, et al. (2003) Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 100:1896-1901. (Pubitemid 36254545)
43. Kustatscher G, Hothorn M, Pugieux C, Scheffzek K, Ladurner AG (2005) Splicing regulates NAD metabolite binding to histone macroH2A. Nat Struct Mol Biol 12: 624-625. (Pubitemid 40980814)
44. Timinszky G, et al. (2009) A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat Struct Mol Biol 16:923-929.